إعلان
إعلان

TPST

TPST logo

Tempest Therapeutics, Inc. Common Stock

2.88
USD
برعاية
+0.09
+3.38%
٠٨ يناير, ١٥:٥١ UTC -5
مغلق
exchange

قبل الإفتتاح

2.89

+0.01
+0.49%

تقارير أرباح TPST

النسبة الإيجابية المفاجئة

TPST تفوق 21 من 37 آخر التقديرات.

57%

التقرير التالي

بيانات التقرير القادم
٢٥ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$3.59
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
+354.43%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-10.92%

Tempest Therapeutics, Inc. Common Stock earnings per share and revenue

On ٠٥ نوفمبر ٢٠٢٥, TPST reported earnings of -0.79 USD per share (EPS) for Q3 25, beating the estimate of -3.33 USD, resulting in a 76.31% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +9.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 المحللين forecast an EPS of -3.59 USD, with revenue projected to reach -- USD, implying an زيادة of 354.43% EPS, and زيادة of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
٢٦ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.49
الفعلي
-
مفاجئة
-
الأسئلة الشائعة
For Q3 2025, Tempest Therapeutics, Inc. Common Stock reported EPS of -$0.79, beating estimates by 76.31%, and revenue of $0.00, 0% as expectations.
The stock price moved up 9.1%, changed from $9.12 before the earnings release to $9.95 the day after.
The next earning report is scheduled for ٢٥ مارس ٢٠٢٦.
Based on 3 المحللين, Tempest Therapeutics, Inc. Common Stock is expected to report EPS of -$3.59 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان